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serum levels of corticosterone after LPS injection was determined
utilizing specific ELISA kits.
Results: Morphine administration per se had no effects on
basal TNF levels. Morphine inhibited intraperitoneal LPS-induced
TNF release but this effect occurred only with high doses
(3.1 and 10mg/kg) and this effect was not dose dependent.
Serum corticosterone levels increased after a single LPS chal-
lenge and morphine dose dependently prevented this effect.
After repeated administration or after morphine withdrawal,
tolerance was developed to morphine inhibitory effects on perit-
oneal TNF release and serum corticosterone levels in response to
LPS.
Conclusions: Morphine inhibitory effects on innate immunity
depend on the opioid administration schedule and duration treat-
ment.
Financial support: Supported by Conacyt (grant 188565 to CGE
and scholarship 219851 to LMM).
http://dx.doi.org/10.1016/j.drugalcdep.2014.02.434
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Aims: Few studies focus specifically on marijuana treatment
outcomes among racial minorities. The present secondary analy-
sis of a clinical trial addresses this gap. It was hypothesized that (1)
African Americans would have higher attrition rates than Whites,
especially during the clinical trial phases following randomization,
(2) overall substance use and retention outcomeswould varywhen
stratified by race and (3) race would moderate the relationship
between treatment type and outcomes.
Methods: 112 court-referred marijuana-dependent young
adults (ages 18–25) were randomized to one of four treatment
conditions: Motivational Enhancement Therapy (MET)/Cognitive
Behavioral Therapy (CBT), MET/CBT+Contingency Management
(CM), Drug Counseling (DC) or DC+CM. African American partici-
pantswere compared toWhite participantswith respect to rates of
participation in phases of treatment and substance use outcomes
using chi-square and t-test analyses. In addition, the interaction
of race and treatment condition was examined via General Linear
Modeling to ascertain if the interventions yielded different effects
based on race.
Results: African Americans were significantly less likely to
complete the treatment and posttreatment phases of the clini-
cal trial than Whites. Irrespective of treatment type, substance
use outcomes did not vary by race. However, there was a signif-
icant interaction effect between treatment type and race; African
Americans did not benefit differentially from any specific type of
treatment, but CM was effective in reducing proportion of mari-
juana positive samples among White youth.
Conclusions: Findings suggest that clinical trial treatment and
posttreatment completion rates vary by race in this population,
as does response to treatment. More treatment research focus-
ing specifically on African American marijuana-dependent youth
is warranted.
Financial support: Funding for this study was provided by
National Institute of Drug Abuse grants P50-DA009241 and R25-
DA020515.
http://dx.doi.org/10.1016/j.drugalcdep.2014.02.435
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Aims: Given the high co-occurrence ofmethamphetamine (MA)
use and HIV infection and the aging of HIV persons in the U.S., we
examined MA use behaviors in relation to age and HIV serostatus.
Considering research indicatingpossible age-related effects onpsy-
chosocial andneuropharmacological factors thatmay affectMAuse
patterns, we hypothesized that the oldest cohort may differ in MA
use behaviors in comparison to younger cohorts.
Methods: Participants included 227 MA-dependent persons
across four 10-year age cohorts (20s:n=22, 30s:n=73, 40s:n=106,
50s: n=26). Individuals underwent extensive substance use, neu-
ropsychological, medical, and psychiatric evaluations. Age cohorts
did not differ on demographic factors or prevalence of psychiatric
comorbidities, other substance use disorders, or HIV infection.
Results: Analyses of variance revealed significant between-
groupdifferences for age of first use, recency of use, and cumulative
days of use (p< .05). The two youngest cohorts initiated use at a
younger age than the next older cohorts, and the oldest cohort
reported more remote use than all other cohorts (ps < .05). Age and
HIV, but not their interaction, significantly predicted age of first use
and cumulative days of use (ps < .0001). Age, HIV, and their interac-
tion significantly predicted total quantity (p< .0001), such that MA
consumption increased with advancing age for HIV− (r= .29), but
not for HIV+ (r= .02), persons.
Conclusions: As compared to their younger counterparts, older
adults had a later onset, greater duration, and earlier cessation of
MA use, which may be driven by psychosocial and/or biomedical
factors. In particular, HIV infection appears to dampen the associa-
tion between older age and greaterMAuse, perhaps due to incident
chronic illness. Older persons without HIV should be assessed for
problematic substance use, which may place them at risk for HIV
transmission.
Financial support: This research was supported by National
Institutes of Health grants P01-DA12065, P50-DA026306, P30-
MH62512, and 5T32DA007315-09.
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